Literature DB >> 16613996

Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry.

Diego Rodríguez Cabaleiro1, Dietmar Stöckl, Jean M Kaufman, Tom Fiers, Linda M Thienpont.   

Abstract

BACKGROUND: Serum C-peptide concentrations reflect pancreatic function in different clinical and diagnostic settings; however, the utility of C-peptide testing is limited by the lack of standardized commercial immunoassays. Standardization can best be done by split-sample comparison with a hierarchically higher reference measurement procedure with a set of native sera. For serum peptides, isotope-dilution liquid chromatography-mass spectrometry (ID-LC/MS) is recommended as a reference measurement procedure.
METHODS: We evaluated the analytical performance characteristics of an ID-LC/tandem MS procedure for measurement of serum C-peptide after a 2-step solid-phase extraction. To investigate the feasibility of this procedure for use in standardization, we also performed a method comparison with 3 representative commercial assays.
RESULTS: The ID-LC/tandem MS procedure showed maximum within-run, between-run, and total CVs on dedicated sera (C-peptide concentrations, 1.6 and 4.0 mug/L) of 2.1%, 2.5%, and 2.9%, respectively; an accuracy of 94.6%-104.1%; a minimum trueness of 98.1% (95% confidence interval, 96.2%-100.0%), and limits of quantification and detection of 0.15 and 0.03 mug/L, respectively. Deming linear regression analysis of the method-comparison data showed that the immunoassays correlated well with ID-MS and were specific, but lacked intercomparability and trueness. We propose that the deficiencies can be resolved by recalibration on the basis of the method comparison.
CONCLUSIONS: The ID-LC/tandem MS procedure is suitable for specific and accurate measurement of basal and stimulated serum concentrations of proinsulin C-peptide fragment 33-63 and is suitable for use in standardization of C-peptide immunoassays.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613996     DOI: 10.1373/clinchem.2005.062505

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

2.  C-peptide microheterogeneity in type 2 diabetes populations.

Authors:  Paul E Oran; Jason W Jarvis; Chad R Borges; Randall W Nelson
Journal:  Proteomics Clin Appl       Date:  2009-11-11       Impact factor: 3.494

3.  Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Authors:  Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

4.  Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care.

Authors:  Myrlene A Staten; Michael P Stern; W Greg Miller; Michael W Steffes; Scott E Campbell
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

5.  Preoperative serum thyroglobulin is a risk factor of skip metastasis in papillary thyroid carcinoma.

Authors:  Ziyang Huang; Muye Song; Shujie Wang; Jianhao Huang; Hongyan Shi; Yijie Huang; Ying Yin; Yongchen Liu; Zeyu Wu
Journal:  Ann Transl Med       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.